Figure 8.

Expression of CSC markers in control, paclitaxel, CYT387 and paclitaxel plus CYT387-treated HEY cells and ascites derived tumor cells. (A) RNA from control and treated HEY cells was extracted, cDNA was prepared and qPCR for EpCAM, CD44, CD117 and Oct4 was performed as described in the Methods section. The resultant mRNA levels were normalized to 18S mRNA. The experiment was performed using four independent samples in triplicate. Significant intergroup variations are indicated by *P <0.05, **P<0.01, ***P < 0.001. (B) Expression and localisation of EpCAM, CD117 in ascites-derived tumor cells in response to paclitaxel, CYT387 and a combination of paclitaxel+CYT387 treatment was evaluated and quantified by immunofluorescence as described in Figure 1. Images are representative of three independent experiments using three independent patient ascites samples. Significant intergroup variations are indicated by *P <0.05, **P < 0.01. (C) The expression and localisation of embryonic stem cell markers NANOG and Oct4 in ascites-derived tumor cells was evaluated and quantified as described in Figure 1. Significant variations between the groups are indicated by *P <0.05, **P<0.01. Magnification 200x; scale bar = 10 μM.

Abubaker et al. BMC Cancer 2014 14:317   doi:10.1186/1471-2407-14-317
Download authors' original image